Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study

Background: The most common type of primary liver cancer is hepatocellular carcinoma (HCC), and hepatitis B virus (HBV)-related HCC accounts for many HCC cases and has a high mortality rate. The goal of our study was to investigate the efficacy and safety of lenvatinib plus sintilimab therapy in rea...

Full description

Bibliographic Details
Main Authors: Lei Zhao, Niajia Chang, Lei Shi, Fengyi Li, Fanglin Meng, Xiaohui Xie, Zhe Xu, Fusheng Wang
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Heliyon
Subjects:
HBV-related hepatocellular carcinoma (HBV-HCC)
Tyrosine kinase inhibitor (TKI)
Immune checkpoint inhibitor (ICI)
Lenvatinib
Sintilimab
Male
Online Access:http://www.sciencedirect.com/science/article/pii/S240584402200826X

Similar Items

Similar Items